Ying S, Robinson D S, Meng Q, Rottman J, Kennedy R, Ringler D J, Mackay C R, Daugherty B L, Springer M S, Durham S R, Williams T J, Kay A B
Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College School of Medicine, London, GB.
Eur J Immunol. 1997 Dec;27(12):3507-16. doi: 10.1002/eji.1830271252.
Eotaxin is a newly discovered C-C chemokine which preferentially attracts and activates eosinophil leukocytes by acting specifically on its receptor CCR3. The airway inflammation characteristic of asthma is believed to be, at least in part, the result of eosinophil-dependent tissue injury. This study was designed to determine whether there is increased expression of eotaxin and CCR3 in the bronchial mucosa of asthmatics and whether this is associated with disease severity. The major sources of eotaxin and CCR3 mRNA were determined by co-localization experiments. Bronchial mucosal biopsy samples were obtained from atopic asthmatics and normal non-atopic controls. Eotaxin and CCR3 mRNA were identified in tissue sections by in situ hybridization (ISH) using radiolabeled riboprobes and their protein product visualized by immunohistochemistry (IHC). Co-localization experiments were performed by double ISH/IHC. Eotaxin and CCR3 (mRNA and protein) were significantly elevated in atopic asthmatics compared with normal controls. In the asthmatics there was a highly significant inverse correlation between eotaxin mRNA+ cells and the histamine provocative concentration causing a 20% fall in FEV1 (PC20). Cytokeratin-positive epithelial cells and CD31+ endothelial cells were the major source of eotaxin mRNA whereas CCR3 co-localized predominantly to eosinophils. These data are consistent with the hypothesis that damage to the bronchial mucosa in asthma involves secretion of eotaxin by epithelial and endothelial cells resulting in eosinophil infiltration mediated via CCR3. Since selective (eotaxin) and non-selective C-C chemokines such as RANTES, MCP-3 and MCP-4 all stimulate eosinophils via CCR3, this receptor is potentially a prime therapeutic target in the spectrum of diseases involving eosinophil-mediated tissue damage.
嗜酸性粒细胞趋化因子是一种新发现的C-C趋化因子,它通过特异性作用于其受体CCR3,优先吸引并激活嗜酸性粒细胞。哮喘特有的气道炎症被认为至少部分是嗜酸性粒细胞依赖性组织损伤的结果。本研究旨在确定哮喘患者支气管黏膜中嗜酸性粒细胞趋化因子和CCR3的表达是否增加,以及这是否与疾病严重程度相关。通过共定位实验确定嗜酸性粒细胞趋化因子和CCR3 mRNA的主要来源。从特应性哮喘患者和正常非特应性对照中获取支气管黏膜活检样本。使用放射性标记的核糖探针通过原位杂交(ISH)在组织切片中鉴定嗜酸性粒细胞趋化因子和CCR3 mRNA,并通过免疫组织化学(IHC)观察其蛋白产物。通过双重ISH/IHC进行共定位实验。与正常对照相比,特应性哮喘患者的嗜酸性粒细胞趋化因子和CCR3(mRNA和蛋白)显著升高。在哮喘患者中,嗜酸性粒细胞趋化因子mRNA +细胞与导致FEV1下降20%的组胺激发浓度(PC20)之间存在高度显著的负相关。细胞角蛋白阳性上皮细胞和CD31 +内皮细胞是嗜酸性粒细胞趋化因子mRNA的主要来源,而CCR3主要与嗜酸性粒细胞共定位。这些数据与以下假设一致:哮喘中支气管黏膜的损伤涉及上皮细胞和内皮细胞分泌嗜酸性粒细胞趋化因子,导致通过CCR3介导的嗜酸性粒细胞浸润。由于选择性(嗜酸性粒细胞趋化因子)和非选择性C-C趋化因子如RANTES、MCP-3和MCP-4均通过CCR3刺激嗜酸性粒细胞,该受体可能是涉及嗜酸性粒细胞介导的组织损伤的一系列疾病中的主要治疗靶点。